Investor Information

News Release

January 20, 2022

MSD K.K. receives manufacturing and marketing approval of LYFNUA® Tablets, world's first selective P2X3 receptor antagonist for the treatment of chronic cough
January 17, 2022

Co-promotion agreement in Japan for oral COVID-19 treatment LAGEVRIO Capsules 200 mg
December 27, 2021

Kyorin Signed Memorandum of Understanding on Co-Promotion of "Lagevrio Capsule 200mg" for COVID-19 Treatment
November 30, 2021

Launch of "Compact Real Time PCR System GeneSoC® mini"
November 8, 2021

Summary of Consolidated Financial Results (For the Second Quarter Ended September 30, 2021) [Japanese Standard]
November 8, 2021

Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information
August 3, 2021

Summary of Consolidated Financial Results (August 3,2021) [Japanese Standard]
August 3, 2021

First Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022 - Supplementary Information

Latest IR Events

Second Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2022

: Top Message

: Products Under Development

: IR Events

: Financial Information

: IR Library

: Stock Information

Annual Report 2021